Short Interest in Ascendis Pharma A/S (NASDAQ:ASND) Drops By 5.1%

Ascendis Pharma A/S (NASDAQ:ASND) was the recipient of a significant decline in short interest during the month of September. As of September 15th, there was short interest totalling 3,340,000 shares, a decline of 5.1% from the August 31st total of 3,520,000 shares. Based on an average trading volume of 572,400 shares, the short-interest ratio is currently 5.8 days.

Institutional Investors Weigh In On Ascendis Pharma A/S

Institutional investors and hedge funds have recently modified their holdings of the company. Private Ocean LLC purchased a new stake in shares of Ascendis Pharma A/S in the 1st quarter valued at $36,000. GAMMA Investing LLC grew its stake in Ascendis Pharma A/S by 52.0% during the 1st quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 102 shares in the last quarter. Bessemer Group Inc. grew its stake in Ascendis Pharma A/S by 61.0% during the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 332 shares in the last quarter. Barometer Capital Management Inc. acquired a new position in Ascendis Pharma A/S during the 4th quarter worth $126,000. Finally, Searle & CO. acquired a new position in Ascendis Pharma A/S during the 2nd quarter worth $205,000.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. JPMorgan Chase & Co. lowered their price target on Ascendis Pharma A/S from $174.00 to $165.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 4th. Citigroup lifted their price target on Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Evercore ISI lifted their price target on Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 17th. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Thursday, September 5th. Finally, Bank of America lifted their price target on Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $195.00.

Ascendis Pharma A/S Stock Down 1.8 %

NASDAQ:ASND opened at $146.60 on Wednesday. Ascendis Pharma A/S has a 52 week low of $85.29 and a 52 week high of $161.00. The company has a market capitalization of $8.54 billion, a P/E ratio of -15.25 and a beta of 0.63. The stock’s fifty day moving average is $134.89 and its two-hundred day moving average is $136.34.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). Ascendis Pharma A/S had a negative net margin of 154.18% and a negative return on equity of 16,574.15%. The business had revenue of $38.75 million during the quarter, compared to analysts’ expectations of $94.74 million. Sell-side analysts anticipate that Ascendis Pharma A/S will post -7.15 earnings per share for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.